Advertisement

Topics

Novartis's canakinumab cut risks for heart attack survivors: study

21:31 EDT 21 Jun 2017 | Reuters

ZURICH (Reuters) - Novartis's investigational medicine canakinumab cut cardiovascular risk for people who had survived a heart attack, the Swiss drugmaker said on Thursday, citing a late-stage study.

Original Article: Novartis's canakinumab cut risks for heart attack survivors: study

NEXT ARTICLE

More From BioPortfolio on "Novartis's canakinumab cut risks for heart attack survivors: study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Acute Coronary Syndromes ACS
Acute Coronary Syndromes (ACS) is an umbrella term for situations where the blood supplied to the heart muscle is suddenly blocked. Treatment for acute coronary syndrome includes medicines and a procedure known as angioplasty, during which doctors inflat...